Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302752 | 0.79 | DAO (0.44) | CYP3A4CASP1RECQLTDP1MAOA | |
| SCHEMBL24265135 | 0.78 | NOS1 (0.41) | CYP3A4ALDH1A1CA12CA1CA2 | |
| SCHEMBL1178110 | 0.77 | EPHX1 (0.45) | ALDH1A1KDM4ELMNA | |
| SCHEMBL13562371 | 0.76 | ACHE (0.48) | CYP3A4ALDH1A1TDP1ARTP53 | |
| SCHEMBL28990905 | 0.75 | CYP3A4 (0.42) | CYP3A4CASP1RECQLALDH1A1CA12 | |
| SCHEMBL112315 | 0.75 | — | — | |
| SCHEMBL29671351 | 0.75 | — | — | |
| SCHEMBL3480429 | 0.74 | AR (0.36) | MAOAAR | |
| SCHEMBL3093787 | 0.74 | MAOA (0.55) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL18720480 | 0.74 | HDAC4 (0.42) | CYP3A4ALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023112764-A1 | RELEASE LAYER-FORMING COMPOSITION AND RELEASE LAYER | 日産化学株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2022040157-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2018116073-A1 | 1, 2, 3-THIADIAZOLE COMPOUNDS AND THEIR USE AS CROP PROTECTING AGENT | PI INDUSTRIES LTD. (IN) | 2018-06-28 | — | — | WO | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120026-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1965805-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | Proskelia SAS (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| WO-2007060026-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2007-05-31 | — | — | WO | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-4006161-A | SEDATIVE, TRANQUILIZER | ELI LILLY AND COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | CYP3A4 795/4885CASP1 931/4885RECQL 377/4885 |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | UTS2R, CACNA1A, CACNA1E | CYP3A4 869/4885CASP1 1232/4885RECQL 332/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CYP3A4 795/4885CASP1 931/4885RECQL 377/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CYP3A4 795/4885CASP1 931/4885RECQL 377/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | CYP3A4 2537/4885CASP1 3330/4885RECQL 19/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | CYP3A4 2429/4885CASP1 2229/4885RECQL 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.